[1] |
Xi Y, Xu PF. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol, 2021; 14, 101174. doi: 10.1016/j.tranon.2021.101174 |
[2] |
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol, 2019; 16, 713−32. doi: 10.1038/s41575-019-0189-8 |
[3] |
Harati-Sadegh M, Sargazi S, Saravani M, et al. Relationship between miR-143/145 cluster variations and cancer risk: proof from a meta-analysis. Nucleosides Nucleotides Nucleic Acids, 2021; 40, 578−91. doi: 10.1080/15257770.2021.1916030 |
[4] |
Wang X, Zbou C, Qiu G, et al. Screening of new tumor suppressor genes in sporadic colorectal cancer patients. Hepato-gastroenterology, 2008; 55, 2039−44. |
[5] |
Wang XL, Zhou CZ, Qiu GQ, et al. Phospholipase C epsilon plays a suppressive role in incidence of colorectal cancer. Med Oncol, 2012; 29, 1051−8. doi: 10.1007/s12032-011-9981-1 |
[6] |
Wang Q, Chen P, Chen DD, et al. Association between phospholipase C epsilon gene (PLCE1) polymorphism and colorectal cancer risk in a Chinese population. J Int Med Res, 2014; 42, 270−81. doi: 10.1177/0300060513492484 |
[7] |
Hu XE, Jia JT, Yang ZY, et al. PLCE1 polymorphisms are associated with gastric cancer risk: the changes in protein spatial structure may play a potential role. Front Genet, 2021; 12, 714915. doi: 10.3389/fgene.2021.714915 |
[8] |
Ezgi O, Merve A, Hakan YT, et al. Genetic variations in phospholipase C-epsilon 1 (PLCE1) and susceptibility to colorectal cancer risk. Biochem Genet, 2016; 54, 826−9. doi: 10.1007/s10528-016-9759-4 |
[9] |
Li FX, Yang XX, He XQ, et al. Association of 10q23 with colorectal cancer in a Chinese population. Mol Biol Rep, 2012; 39, 9557−62. doi: 10.1007/s11033-012-1820-8 |
[10] |
Kupcinskas J, Gyvyte U, Bruzaite I, et al. Common genetic variants of PSCA, MUC1 and PLCE1 genes are not associated with colorectal cancer. Asian Pac J Cancer Prev, 2015; 16, 6027−32. doi: 10.7314/APJCP.2015.16.14.6027 |